Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Kousuke Matsui

14PUBLICATIONS
97CO-AUTHORS
HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunityCardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

Sort by Publication Date:
|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|Apr 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

|Apr 10, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka

|Mar 21, 2026
The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy.

Van Khanh Nguyen, Kosuke Matsui, Hisashi Kosaka

|Feb 26, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka

|Jan 09, 2026
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.

Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada

Pageof 3

Frequent Collaborators

13 joint publications

Masaki Kaibori

11 joint publications

Hisashi Kosaka

9 joint publications

Fujimasa Tada

9 joint publications

Hidenori Toyoda

9 joint publications

Ei Itobayashi

9 joint publications

Takeshi Hatanaka

9 joint publications

Takashi Kumada

9 joint publications

Toshifumi Tada

8 joint publications

Kazuya Kariyama

8 joint publications

Masanori Atsukawa

Frequent Collaborators

13 joint publications

Masaki Kaibori

11 joint publications

Hisashi Kosaka

9 joint publications

Fujimasa Tada

9 joint publications

Hidenori Toyoda